Psychedelic Frontiers Series – Part 5 | Unpacking the Latest Developments in the World of Psychedelic Medicine
In Psychedelic Frontiers: Diverse Perspectives on a Mental Health Revolution, FTI Consulting experts embark on a journey to explore the various ways in which psychedelic medicine is perceived across different stakeholder groups, including the research community, medical and mental health providers, and political stakeholders. The series aims to underscore the nuances of communicating about psychedelic medicines with vested parties, especially in regard to the therapeutic potential of these substances amid the growing mental health crisis.
On July 13, several federal agencies issued a series of announcements surrounding psychedelic medicines, indicating a stark shift in the policy and regulatory environment.1 Rooted in President Trump’s April 2026 executive order fast-tracking review of psychedelics for mental health disorders,2 this week’s actions ran the full length of the development pipeline – from research funding to regulatory pathways to readiness. On the regulatory side, the Department of Health and Human Services (HHS) and Veterans Affairs (VA) signed a memorandum of understanding to accelerate clinical trials of these emerging therapies,3 while the Food and Drug Administration (FDA) released final guidance for clinical investigations around these drugs,4 and scheduled a public hearing on future therapeutic uses.5
On the research side, the National Institute on Drug Abuse (NIDA) shared revived and validated ibogaine data with the FDA and awarded funding toward an Investigational New Drug (IND) application for opioid use disorder, and the Advanced Research Projects Agency for Health (ARPA-H) opened a competition to fund early clinical development of the same compound.6,7 And on the readiness side, the Health Resources and Services Administration (HRSA) issued a Request for Information the following day on how the healthcare workforce and community-based care system should prepare to deliver these therapies once approved.8
Days later, on July 16, Eli Lilly – the world’s most valuable healthcare company – agreed to acquire psychedelic drugmaker AtaiBeckley for roughly $2.8 billion upfront, with contingent payments that could bring the total to $3.8 billion.9
Two major announcements in the span of one week – a clear signal that momentum is picking up serious speed regarding these emerging therapies.
The Unmet Need is Undeniable
The clinical case for psychedelic medicines is grounded in a documented gap in care. More than 62 million American adults are living with mental illness, while 137 million Americans reside in areas with behavioral health provider shortages.10,11 Even among those diagnosed, fewer than half receive timely care.12 The need is particularly acute among veterans, a population now positioned at the center of federal action. One in four veterans has a documented mental health condition, and more than half do not receive treatment, with high rates of treatment-resistant PTSD and depression underscoring the urgency for new therapeutic approaches.13,14 Innovative treatment modalities, like these emerging therapies currently in clinical development, present a solution that could address these gaps.
From Taboo to Mainstream: The Market Has Moved
With the clinical case clearly established and the potential benefits of these emerging therapies widely touted for some time, the momentum shift has been building within the regulatory environment as well as the pharmaceutical industry. Moreover, federal actions this week strengthen the case for pharmaceutical companies that have been watching from the sidelines, as these policy directives open the door for investment in this market.
Recent trends indicate an already-shifting M&A landscape for the psychedelics market. Spravato – the only currently approved psychedelic-adjacent psychiatric treatment – generated $1.7 billion in sales for Johnson & Johnson in 2025, demonstrating psychedelic treatments’ potential for mainstream adoption and significant commercial success.15 AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ psychedelic compound in the same year marked the first such acquisition by a traditional pharmaceutical company.16 In under a year, psychedelics moved from a category a single large pharmaceutical company was willing to take a risk on to one Eli Lilly – the industry’s most valuable company – was willing to anchor a neuroscience strategy on.
Once a niche research market, psychedelic medicines are now becoming a mainstream pharmaceutical investment prospect. This milestone takes on even greater significance against the backdrop of the $300 billion patent cliff that Big Pharma faces over the next several years as a number of blockbuster drugs stand to lose patent exclusivity. The resulting financial pressures may further drive interest in these emerging therapies as a high-growth pipeline opportunity as pharmaceutical companies seek to offset patent losses.17 Eli Lilly’s move illustrates the logic directly: analysts framed the acquisition as adding a platform of rapid-acting therapies and broadening the company’s neuroscience portfolio into treatment-resistant depression and other hard-to-treat psychiatric disorders — precisely the high-growth, high-unmet-need categories Big Pharma is racing to secure.18
The Field of Buyers is Widening
Eli Lilly is not the first mover; it is the latest and largest in a field of buyers that has been quietly expanding. Johnson & Johnson, through its Janssen unit, brought the category’s anchor product to market with Spravato and has continued to build out its neuroscience franchise — including its acquisition of Intra-Cellular Therapies and its bipolar-depression therapy CAPLYTA.19 Otsuka has been among the most active strategic players, agreeing to acquire methylone developer Transcend Therapeutics in a deal valued at up to $1.23 billion and partnering earlier with AtaiBeckley’s Perception Neuroscience unit on R-ketamine — the first major collaboration between a psychedelic-focused biotech and a large pharmaceutical company.20,21 AbbVie, whose Gilgamesh transaction is noted above, is already inside the tent.
The list of pharmaceutical companies with the strategic logic to move is longer still. Following the commercial validation of Spravato, industry observers have reported that firms including Compass Pathways, J&J, and Otsuka are actively evaluating the space for future transactions, while others with established psychiatry pipelines — Boehringer Ingelheim among them — have the neuroscience infrastructure to enter quickly should they choose to.22,23 The common profile is consistent: an existing psychiatry or CNS commercial base, meaningful exposure to patent expirations, prior deal activity in adjacent neuroscience categories, and the operational capability to commercialize therapies that require controlled administration settings.
For the emerging companies on the other side of the table, the implication is direct. A maturing bench of late-stage assets — from psilocybin programs in Phase 3 to DMT-, MDMA-, and LSD-based candidates advancing through the clinic — means the question facing many developers is no longer only whether their science will succeed, but how they will be positioned, valued, and communicated to when strategic interest arrives. In a market moving this quickly, the pharmaceutical companies that have already defined their narrative and their stakeholder relationships will negotiate from a position of strength while those that have not will find the terms defined for them.
The Challenges Are as Real as the Opportunity
Despite momentum, pharmaceutical companies operating in this space still face a distinct and layered set of risks. The stigma against these emerging therapies has not disappeared, and cultural resistance may continue to affect stakeholder confidence and support from policymakers and the public. In addition, fragmented state versus federal frameworks,24 evolving Drug Enforcement Administration (DEA) classification of these emerging therapies,25 and unclear FDA pathways create compliance and market access uncertainties that require expert navigation.26 Pharmaceutical companies in this market also operate under intense scrutiny, while facing elevated exposure to litigation and reputational vulnerabilities. And as M&A activity accelerates, companies must be prepared to manage deal speculation and transaction complexity across a broad set of internal and external stakeholders. The AtaiBeckley transaction is instructive: the target’s shares surged roughly 66% on unconfirmed reports of talks, days before terms were public — a reminder that in this environment, market-moving speculation can outpace a company’s ability to control its own narrative.27
Additionally, psychedelic medicines may also be arriving before the systems needed to support them are in place. These treatments do not fit the infrastructure built for traditional behavioral health programs: they require supervised, in-clinic administration, hours-long monitored dosing sessions, specially trained clinicians, and — for compounds like ibogaine, with its documented cardiac risks28 — cardiology and monitoring capabilities that most behavioral health settings do not currently have.29
That gap is not only a challenge for drug developers; it is a set of openings across the wider healthcare ecosystem. Health systems and interventional-psychiatry programs that build administration capacity, protocols, and referral pathways now can position themselves as early centers of excellence and capture a new service line, much as the Spravato REMS model demonstrated is possible.30 Academic medical centers and research institutions stand to benefit directly from the NIH and ARPA-H funding streams — as trial sites, IND sponsors, and the source of the evidence base that will define the field — while the HHS-VA partnership turns VA medical centers and their academic affiliates into ready-made clinical trial infrastructure. Community-based providers named in HRSA’s inquiry — Federally Qualified Health Centers, Rural Health Clinics, and Certified Community Behavioral Health Clinics — have an opening to extend access into underserved and rural areas, supported by future federal guidance and technical assistance.31
And the workforce itself may be the most immediate opportunity of all: with HRSA actively soliciting input on clinician education, training, and care-delivery models, medical schools, nursing programs, and credentialing bodies that engage now can help write the standards rather than inherit them. The work of building capacity and shaping the emerging rules an advantage available to those who move before the approvals arrive, not after.
How these factors are navigated will determine which pharmaceutical companies are positioned to effectively capitalize on this market, and which struggle to gain traction. Success in the psychedelic medicines market requires more than a strong clinical program. Rather, pharmaceutical companies must shape the public narrative, positioning these emerging therapies as evidence-based medicine grounded in science. Success also requires managing and de-risking regulatory pathways through integrated teams with fluency across governance, policy, media, and regulatory risk.
The window is not theoretical, and it is not wide. With the sector’s largest and most credentialed buyer now committed, the competition for the next generation of assets, partnerships, and public trust has visibly begun. The September FDA public hearing on psychedelic medicines is expected to draw significant attention from policymakers, investors, and the media.32 Pharmaceutical companies that arrive at that moment with clear positioning and credible narratives will be considerably better positioned than those still working to respond to a market that is already consolidating.
FTI Consulting: Built for This Moment
FTI Consulting brings a unique combination of healthcare expertise, regulatory fluency, and strategic communications capability to support the psychedelic medicines market in this moment. Our Healthcare and Life Sciences practice includes more than 575 experts — among them former CEOs, CMOs, and clinical leaders — with a track record of guiding industry-leading companies through major business transformations, regulatory shifts, crisis scenarios, and reputational challenges. Our Strategic Communications team has deep experience building messaging platforms that resonate and turning them into high-impact campaigns that shape perception, drive engagement, and earn trust across audiences. Our M&A advisory capabilities span the full transaction lifecycle — from due diligence and integration planning to investor communications and regulatory clearance. And our capabilities extend beyond drug developers to the health systems, academic medical centers, and community providers now preparing to deliver these therapies — advising on service-line strategy, clinical and workforce readiness, research partnerships, and regulatory engagement as they build the capacity this moment will demand.
The federal government has made its move, and pharmaceutical companies are following suit. The psychedelic medicines market is no longer a question of if, but of who will be ready when the approvals come. Stakeholders will need a partner with perspective, precision, and a track record of delivering in complex environments. This is the kind of work FTI Consulting does best — and the kind of moment for which we are built.
For more information, contact Julie Carney, Managing Director, Public Affairs, at [email protected], or Michael Adeyanju, Managing Director, Public Affairs, at [email protected].
Indya Adam, an intern for the Strategic Communications segment at FTI Consulting during the 2026 summer session, contributed to this article.
Related Insights
Related Expertise
The views expressed herein are those of the author(s) and not necessarily the views of FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals.
FTI Consulting, Inc., including its subsidiaries and affiliates, is a consulting firm and is not a certified public accounting firm or a law firm.
FTI Consulting is an independent global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. FTI Consulting professionals, located in all major business centers throughout the world, work closely with clients to anticipate, illuminate and overcome complex business challenges and opportunities. ©2026 FTI Consulting, Inc. All rights reserved. www.fticonsulting.com
